OR WAIT null SECS
The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally.
The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally, whereby innovators are mapping out a product’s full lifecycle as early as the pre-clinical stage.
According to an Aug. 19, 2022 press release, a key finding published in the report is that ‘pharma-ready’ synthetic routes are being planned much earlier in the development process, with ‘phase-appropriate development’ being believed to be an outdated approach, particularly when dealing with accelerated pathways. It is suggested in the report that innovators will need to choose either a single end-to-end provider or a multi-provider model and that contract development and manufacturing organizations (CDMOs) will need to rethink their approaches to development and marketing.
“This report highlights that innovators need to meet contract services partners sooner, plan much earlier and far further into development,” said Orhan Caglayan, brand director at CPHI Frankfurt, in the press release. “We are evolving CPHI Frankfurt to help both CDMOs and innovators adapt to this shift in approach by providing new insights and more networking opportunities for early-stage companies attending the event. Over the next few years, we anticipate many more biotechs will use CPHI to map out their potential partners long before IND. Exploring what type of outsourcing approach will best fit their products development and even commercial needs.”
The full report is available for download.